МегаБлог

МегаБлог- – это объединение постов из популярных трейдерских блогов . Этот раздел позволит отслеживать интересные темы и проследить популярные тенденции в трейдинге, понять чем живут трейдеры.

The second day at the MICEX

Not a bad day turned out to, of course in the morning went to -0.3% trying to sell Gazprom, but he did not go, had to buy it) All day traded Gazprom and Lukoil, has made almost 1% of the depot, but LUKOIL away and did not let me. As a result, day +0.6% Few of my transactions, it’s not all and not quite accurate: oops: Gazprom:

Exclusive Interview: Charles Kirk from The Kirk Report

Have you ever heard of the investor who grew $2000 into more than $1 million? Meet Charles Kirk. Charles is not your average fast-talking, infomercial-star pitching to sell you his get-rich-quick scam. Rather, Charles is one of the most respected investing and trading bloggers on the web. Charles is best know for The Kirk Report: a blog which provides readers with a steady flow of excellent tips for becoming a better investor or trader. He works hard to help educate people on how to build a skill set which will benefit them for a lifetime. Rather than promise quick riches, Charles takes pride in being honest when explaining the time and discipline required to become a successful investor. In a business full of charlatans, Charles is a gem. I sat down with Charles to discuss his ride to millionaire status, his widely-read blog The Kirk Report, what it’s like to be a good-guy on Wall Street, and what it takes to follow in his footsteps … Damien Hoffman: Charles, we both bailed on a law career. Can you share how you transitioned from law school to stocks and blogging?

Торговые идеи на 4 сентября

Symbol SELL BUY AMX 43 44.5 FMX 34.3 36 GAZ 12 0 GDX 0 45 GES 33.5 36 GVA 30 0 HOT 27 28.4 IAG 0 14.6 KGC 0 22.2 LO 71 73.5 MCO 23 24.5 MHP 28.3 29.5 MVL 47 49 OSK 31 32.6 SYK 0 42.5 WLT 0 55.5

Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History

PHILADELPHIA, Sept 02, 2009 /PRNewswire-USNewswire via COMTEX/ — Includes Allegations of Illicitly Promoting Antibiotic As Clinically Superior When Its Own FDA-Approved Label Said Otherwise; First-Ever Qui Tam Whistleblower Settlement of Its Type Pfizer Inc. ignored a 2005 FDA Warning Letter to stop promoting its antibiotic Zyvox(R) as clinically superior to the significantly less expensive, generic vancomycin when its own FDA-approved label indicated otherwise. The drug giant also defrauded federal and state taxpayers by marketing Zyvox off-label, according to a qui tam whistleblower complaint filed by Philadelphia law firm Sheller, P.C. and other documents unsealed with today’s $2.3 billion Pfizer settlement. The $2.3 billion settlement included off-label marketing allegations for the withdrawn arthritis drug Bextra(R), which was included in the Sheller complaint. Zyvox (linezolid) is an antibacterial agent that is approved by the FDA to treat certain types of infections, including nosocomial pneumonia and complicated skin and skin structure infections (“CSSSIs”) due to Methicillin Resistant Staphylococcus Aureus (“MRSA”). Worldwide sales of Zyvox totaled $1.115 billion in 2008.

Пролистать наверх